Appendix D
Public Meeting Agendas
Committee on Vaccine Research and Development for Advancing Pandemic and Seasonal Influenza Preparedness and Response
First Committee Meeting Agenda
March 8 and 10, 2021
Orientation and Conflict of Interest Discussion: March 8, 7:00–9:30 PM EST
Speaker Session: March 10, 7:00–10:00 AM EST
Planning/Working Session: March 10, 3:30–6:30 PM EST
Virtual
Monday, March 8, 2021
7:30–8:30 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY
8:30–9:00 PM EST OPEN SESSION
| 8:30 PM | Sponsor Perspective on Charge to the Committee |
| 8:45 PM | Q&A for Sponsor |
9:00–9:30 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY
| 9:30 PM | Adjourn |
Wednesday, March 10, 2021
7:00–9:00 AM EST OPEN SESSION
| 7:00 AM | Welcome and Opening Remarks |
| 7:10 AM |
COVID-19 Response: Lessons Learned NADINE ROUPHAEL Department of Medicine, Division of Infectious Diseases Emory University School of Medicine |
| 7:30 AM | Discussion with Committee |
| 7:45 AM |
Regulatory Pathways in the United States to Facilitate Vaccine Availability PETER MARKS Center for Biologics Evaluation and Research U.S. Food and Drug Administration |
| 8:00 AM | Discussion with Committee |
| 8:10 AM | Break |
| 8:15 AM |
Overview of the Influenza Vaccines R&D Roadmap and the Universal Influenza Vaccine Technology Landscape JULIE OSTROWSKY Center for Infectious Disease Research and Policy University of Minnesota |
| 8:40 AM | Discussion with Committee |
| 8:55 AM | Break |
9:00–10:00 AM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY
| 10:00 AM | Adjourn Morning Session |
Wednesday, March 10, 2021
3:30–6:30 PM EST CLOSED SESSION
Second Committee Meeting
March 30, 2021
3:00–6:00 PM EST
Virtual
March 30, 2021
3:00–4:30 PM EST OPEN SESSION
| 3:00 PM | Welcome, Review of Previous Session |
| 3:10 PM |
Broadly Protective and Universal Influenza Virus Vaccines in Development FLORIAN KRAMMER Professor in Vaccinology Department of Microbiology Icahn School of Medicine at Mount Sinai |
| 3:25 PM | Discussion with Committee |
| 3:35 PM |
Perspective on Lessons from the COVID-19 Vaccine Experience BARNEY GRAHAM Deputy Director, Vaccine Research Center Chief, Viral Pathogenesis Laboratory and Translational Science Core National Institutes of Health |
| 3:50 PM | Discussion with Committee |
| 4:00 PM |
Vaccinating Against Influenza Viruses: Can New Memory Be Induced When Old Memory Is Recalled ANNETTE FOX Senior Research Scientist World Health Organization Collaborating Centre for Reference and Research on Influenza University of Melbourne |
| 4:15 PM | Discussion with Committee |
| 4:25 PM | Break, End of Open Session |
4:30–6:00 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY
Third Committee Meeting
April 15, 2021
3:00–6:00 PM EST
Virtual
April 15, 2021
3:00–4:15 PM EST OPEN SESSION
| 3:00 PM | Welcome, Review of Previous Session |
| 3:10 PM |
Overview of Novel Platforms in Influenza Vaccine and Integrating Lessons from COVID-19 REBECCA COX Professor of Medical Virology and Head of the Influenza Centre University of Bergen |
| 3:25 PM | Discussion with Committee |
| 3:35 PM |
Lessons Learned from COVID-19 Vaccine Development MELANIE SEVILLE Director of Vaccine Development Coalition for Epidemic Preparedness Innovations |
| 3:50 PM | Discussion with Committee |
| 4:10 PM | Break, End of Open Session |
4:15–6:00 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY
Fourth Committee Meeting
April 28, 2021
3:00–6:00 PM EST
Virtual
April 28, 2021
3:00–3:20 PM EST CLOSED SESSION
3:20–4:30 PM EST OPEN SESSION
| 3:20 PM | Introduction to Open Session |
| 3:30 PM |
Overview of Vaccine Clinical Trials in Lower- and Middle-Income Countries MILAGRITOS TAPIA Professor of Pediatrics and Medicine University of Maryland at Baltimore |
| 3:45 PM | Discussion with Committee |
| 4:00 PM |
Influenza Vaccines in LMICs: Manufacturing and Feasibility Considerations KATHY NEUZIL Director, Center for Vaccine Development University of Maryland School of Medicine |
| 4:15 PM | Discussion with Committee |
| 4:25 PM | Break, End of Open Session |
4:30–6:00 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY
Fifth Committee Meeting
May 12, 2021
8:00–11:00 AM EST
Virtual
May 12, 2021
8:00–9:30 AM EST OPEN SESSION
| 8:00 AM | Introduction to Open Session |
| 8:10 AM |
Lessons from COVID-19 for Influenza Preparedness JEROME KIM Director General International Vaccine Institute |
| 8:25 AM | Discussion with Committee |
| 8:35 AM |
Understanding Vaccine Effectiveness: Lessons from COVID-19 and Applications for Influenza BEN COWLING Professor of Epidemiology and Biostatistics School of Public Health The University of Hong Kong |
| 8:50 AM | Discussion with Committee |
| 9:00 AM |
Successes and Challenges in Monitoring Vaccine Safety in the United States GRACE LEE Professor of Pediatrics Stanford University School of Medicine |
| 9:30 AM | Break, End of Open Session |
9:30–11:00 AM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY
Sixth Committee Meeting
May 26, 2021
3:00–6:00 PM EST
Virtual
May 26, 2021
3:00–4:30 PM EST OPEN SESSION
| 3:00 PM | Welcome, Review of Previous Session |
| 3:05 PM |
Successes in Technology Transfer and Manufacturing Partnerships: Lessons from COVID-19 and Applications for Influenza MARIA ELENA BOTTAZI Associate Dean and Professor Baylor College of Medicine |
| 3:15 PM | Discussion with Committee |
| 3:25 PM |
Manufacturing Science of Influenza Vaccine Research and Development ROBERT JOHNSON Director, Influenza and Emerging Infectious Diseases Division and COVID-19 Incident Manager Biomedical Advanced Research Development Authority |
| 3:35 PM | Discussion with Committee |
| 3:45 PM |
Developing Vaccines in the Era of Genomics RINO RAPPUOLI Chief Scientist and Head of External Research and Development GlaxoSmithKline |
| 3:55 PM | Discussion with Committee |
| 4:05 PM |
Manufacturing Science of Influenza Vaccine R&D: Mind the Adjacencies DAVID KASLOW Chief Scientific Officer PATH |
| 4:15 PM | Discussion with Committee |
| 4:30 PM | Break, End of Open Session |
4:30 PM–6:00 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY
Seventh Committee Meeting
June 10, 2021
3:00–6:00 PM EST
Virtual
June 10, 2021
3:00–4:30 PM EST OPEN SESSION
| 3:00 PM | Welcome |
| 3:10 PM | Opening Remarks by Joshua Sharfstein |
| 3:15 PM |
Key Considerations for Vaccine Research and Development PHIL DORMITZER Vice President and Chief Scientific Officer: Viral Vaccines Pfizer Inc. |
| 3:30 PM |
Key Considerations for Vaccine Research and Development RITA HELFAND Chair World Health Organization Global Advisory Committee for Vaccine Safety |
| 3:25 PM |
Key Considerations for Vaccine Research and Development NICOLE LURIE Director, Strategic Advisor to the Chief Executive Officer Coalition for Epidemic Preparedness Initiatives |
| 3:30 PM | Panel: Regulatory Science of Vaccine Development |
| 4:30 PM | Break, End of Open Session |
4:30–6:00 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY
This page intentionally left blank.
